An Observational Post-Authorization Safety Surveillance (PASS) Study of SYCREST® (asenapine) among Patients aged 18 and older Diagnosed with Bipolar Disorder (P08307)First published 24/05/2017 Last updated 02/07/2024 EU PAS number: EUPAS17631StudyFinalised